Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies

被引：196

作者：

Siegler, Elizabeth L. ^{[1
,2
]}

Kenderian, Saad S. ^{[1
,2
,3
,4
]}

机构：

[1] Mayo Clin, T Cell Engn, Rochester, MN 55905 USA

[2] Mayo Clin, Div Hematol, Rochester, MN 55905 USA

[3] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA

[4] Mayo Clin, Dept Mol Med, Rochester, MN 55905 USA

来源：

FRONTIERS IN IMMUNOLOGY | 2020年 / 11卷

关键词：

CART; chimeric antigen receptor; immunotherapy; CRS; neurotoxicity; B-CELL; ADOPTIVE IMMUNOTHERAPY; INHIBITOR IBRUTINIB; GENE; TOXICITIES; TRIAL; PERSISTENCE; REMISSIONS; ACTIVATION; BIOMARKERS;

D O I：

10.3389/fimmu.2020.01973

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Chimeric antigen receptor T (CART) cell immunotherapy has been remarkably successful in treating certain relapsed/refractory hematological cancers. However, CART cell therapy is also associated with toxicities which present an obstacle to its wider adoption as a mainstay for cancer treatment. The primary toxicities following CART cell administration are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). New insights into the mechanisms of these toxicities have spurred novel treatment options. In this review, we summarize the available literature on the clinical manifestations, mechanisms, and treatments of CART-associated CRS and ICANS.

引用

页数：11

共 99 条

[1] Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory ( R/R) Large B Cell Lymphomas [J].

Abramson, Jeremy S. ;

Palomba, Maria Lia ;

Gordon, Leo I. ;

Lunning, Matthew A. ;

Wang, Michael L. ;

Arnason, Jon E. ;

Mehta, Amitkumar ;

Purev, Enkhtsetseg ;

Maloney, David G. ;

Andreadis, Charalambos ;

Sehgal, Alison R. ;

Solomon, Scott R. ;

Ghosh, Nilanjan ;

Albertson, Tina ;

Garcia, Jacob ;

Kostic, Ana ;

Li, Daniel ;

Kim, Yeonhee ;

Siddiqi, Tanya .

BLOOD, 2019, 134

[2]

[Anonymous], 2015, BLOOD, DOI DOI 10.1182/blood.V126.23.2524.2524

[3]

[Anonymous], 2018, BLOOD S1, DOI [DOI 10.1182/BLOOD-2018-99-119502, DOI 10.1038/nm.3909]

[4]

[Anonymous], 2015, BLOOD, DOI DOI 10.1182/BLOOD.V126.23.683.683

[5] CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia [J].

Brentjens, Renier J. ;

Davila, Marco L. ;

Riviere, Isabelle ;

Park, Jae ;

Wang, Xiuyan ;

Cowell, Lindsay G. ;

Bartido, Shirley ;

Stefanski, Jolanta ;

Taylor, Clare ;

Olszewska, Malgorzata ;

Borquez-Ojeda, Oriana ;

Qu, Jinrong ;

Wasielewska, Teresa ;

He, Qing ;

Bernal, Yvette ;

Rijo, Ivelise V. ;

Hedvat, Cyrus ;

Kobos, Rachel ;

Curran, Kevin ;

Steinherz, Peter ;

Jurcic, Joseph ;

Rosenblat, Todd ;

Maslak, Peter ;

Frattini, Mark ;

Sadelain, Michel .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (177)

[6] Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy [J].

Brown, Christine E. ;

Alizadeh, Darya ;

Starr, Renate ;

Weng, Lihong ;

Wagner, Jamie R. ;

Naranjo, Araceli ;

Ostberg, Julie R. ;

Blanchard, M. Suzette ;

Kilpatrick, Julie ;

Simpson, Jennifer ;

Kurien, Anita ;

Priceman, Saul J. ;

Wang, Xiuli ;

Harshbarger, Todd L. ;

D'Apuzzo, Massimo ;

Ressler, Julie A. ;

Jensen, Michael C. ;

Barish, Michael E. ;

Chen, Mike ;

Portnow, Jana ;

Forman, Stephen J. ;

Badie, Behnam .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (26) :2561-2569

[7] Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma [J].

Brown, Christine E. ;

Badie, Behnam ;

Barish, Michael E. ;

Weng, Lihong ;

Ostberg, Julie R. ;

Chang, Wen-Chung ;

Naranjo, Araceli ;

Starr, Renate ;

Wagner, Jamie ;

Wright, Christine ;

Zhai, Yubo ;

Bading, James R. ;

Ressler, Julie A. ;

Portnow, Jana ;

D'Apuzzo, Massimo ;

Forman, Stephen J. ;

Jensen, Michael C. .

CLINICAL CANCER RESEARCH, 2015, 21 (18) :4062-4072

[8] T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma [J].

Brudno, Jennifer N. ;

Maric, Irina ;

Hartman, Steven D. ;

Rose, Jeremy J. ;

Wang, Michael ;

Lam, Norris ;

Stetler-Stevenson, Maryalice ;

Salem, Dalia ;

Yuan, Constance ;

Pavletic, Steven ;

Kanakry, Jennifer A. ;

Ali, Syed Abbas ;

Mikkilineni, Lekha ;

Feldman, Steven A. ;

Stroncek, David F. ;

Hansen, Brenna G. ;

Lawrence, Judith ;

Patel, Rashmika ;

Hakim, Frances ;

Gress, Ronald E. ;

Kochenderfer, James N. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) :2267-+

[9] Toxicities of chimeric antigen receptor T cells: recognition and management [J].

Brudno, Jennifer N. ;

Kochenderfer, James N. .

BLOOD, 2016, 127 (26) :3321-3330

[10] Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma [J].

Budde, Lihua E. ;

Berger, Carolina ;

Lin, Yukang ;

Wang, Jinjuan ;

Lin, Xubin ;

Frayo, Shani E. ;

Brouns, Shaunda A. ;

Spencer, David M. ;

Till, Brian G. ;

Jensen, Michael C. ;

Riddell, Stanley R. ;

Press, Oliver W. .

PLOS ONE, 2013, 8 (12)

← 1 2 3 4 5 6 7 8 9 10 →